BioAffinity Technologies announced that Michael Dougherty has resigned as CFO to accept a CFO position in the Pacific Northwest in the energy industry. J. Michael Edwards, who served as BioAffinity’s consulting CFO from 2014 to 2023 and oversaw the company’s initial public offering in 2022, will serve as interim CFO until a permanent CFO is appointed. Dougherty will continue to serve in the role of CFO until Sept. 15 and will assist in the transition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- Mars buys Kellanova, Cardinal Health reports Q4 beat: Morning Buzz
- BioAffinity Technologies reports Q2 EPS (19c), consensus (17c)
- Maxim starts BioAffinity Technologies at Buy on CyPath Lung potential
- BioAffinity Technologies initiated with a Buy at Maxim
- BioAffinity reports 217% revenue growth for CyPath Lung in Q2